Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)

NCT04037254 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04037254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04037254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Lead sponsor
NRG Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
October 8, 2019
Completion date
December 23, 2025
Enrollment
22 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iva prostate cancer ajcc v8